Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma

• Published in: Thorax 1990-04, Vol.45 (4), p.259-261
• Main Authors: Wallin, A, Melander, B, Rosenhall, L, Sandström, T, Wåhlander, L
• Format: Article
• Language: English
• Subjects: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists - administration & dosage; Adrenergic beta-Agonists - therapeutic use; Adult; Aerosols; Aged; Albuterol - administration & dosage; Albuterol - therapeutic use; Asthma - drug therapy; Bronchodilator Agents - administration & dosage; Bronchodilator Agents - therapeutic use; Chronic Disease; Double-Blind Method; Ethanolamines - administration & dosage; Ethanolamines - therapeutic use; Female; Formoterol Fumarate; Humans; Male; Middle Aged; Peak Expiratory Flow Rate - drug effects; Randomized Controlled Trials as Topic; Time Factors
• ISSN: 0040-6376; 1468-3296
• DOI: 10.1136/thx.45.4.259

Sixteen patients with stable chronic asthma participated in a double blind crossover study comparing the new inhaled long acting beta 2 agonist formoterol with salbutamol. Inhaled (n = 15) and oral steroid (n = 1) treatment were maintained at the same daily dose throughout the study. For four weeks the patients received either formoterol 24 micrograms twice daily or salbutamol 400 micrograms twice daily, plus additional puffs (with the same drug) when needed. Asthma symptoms, additional puffs of beta 2 agonist, peak expiratory flow (PEF), and side effects were recorded daily. During treatment with formoterol the patients used fewer additional puffs of beta 2 agonist, had better symptom scores, less disturbed sleep, more days without additional aerosol, and higher PEF both morning and evening than during salbutamol treatment. Thus formoterol 24 micrograms twice daily gave long lasting bronchodilatation and asthma symptoms were well controlled with regular twice daily administration.